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Theactivityoftheanti-CD20monoclonalantibody,rituximabinB-cellnon-Hodgkin’slymphoma,withrelativelyminimaltoxicity
has been well established. Adverse eﬀects such as low-grade fever, urticaria, bronchospasm, sporadic tachycardia, and hypotension
have been described. However, only a single case of rituximab-related, transient conjunctivitis has been documented in literature.
We report an occurrence of chronic, bilateral conjunctivitis in an 88-year-old female diagnosed with stage IV, non-Hodgkin’s
lymphoma (NHL), who was maintained on rituximab for 12 months. In contrast to the previously described case, our patient
developed severe conjunctival inﬂammation approximately three to four weeks following rituximab induction. Resolution of
conjunctivitis occurred within two months after cessation of rituximab treatment.
Copyright © 2009 Marnelli A. Bautista et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The chimeric, anti-CD20 monoclonal antibody, rituximab
plays a signiﬁcant role in the management of B-cell non-
Hodgkin’s lymphomas. Beneﬁt from this agent has been
observed in both low-grade and high-grade lesions [1–5]. In
addition, its low-toxicity proﬁle has made it a suitable pref-
erence as part of the initial treatment panel for most patients
with B-cell lymphoma. Adverse reactions consist of low-
grade fever, urticaria, rhinitis, lacrimation, bronchospasm,
occasional hypotension, and tachycardia. Only one case of
conjunctivitis has been reported [6].
We report a case of signiﬁcant, chronic conjunctivitis in
an 88-year-old female with low-grade follicular lymphoma,
who was maintained on rituximab for one year. The patient
developed mild, bilateral eye inﬂammation approximately
three to four weeks within the induction cycle. She expe-
rienced aggravation of the conjunctivitis with subsequent
rituximab treatments.
2.Casereport
An 88-year-old female with insidious onset of dyspnea on
exertion and occasional nonproductive cough was found
to have a 5.7cm right hilar mass on chest x-ray. A CT-
guided biopsy of the soft tissue mass showed a diﬀuse,
monotonous inﬁltrate of small to medium-sized lympho-
cytes. Mitotic ﬁgures were not signiﬁcantly increased, with
only approximately 5% of the tumor cell nuclei exhibiting
Ki-67reactivity.Thepredominantlymphocyteswerepositive
for CD20, CD10, and Bcl-6 and negative for CD3 and Cyclin
D1 markers.
Bone marrow biopsy was performed to assess systemic
involvement. The core biopsy revealed a normocellular
marrow for age with a single, paratrabecular lymphoid
aggregate (Figure 1), demonstrating similar immunohisto-
chemical staining pattern to that of the right hilar mass.
The characteristic features of the malignant cells in the
mediastinum and bone marrow were consistent with a stage
IV, low-grade, follicular B-cell lymphoma.
Radiationtothemediastinalmasswasinitiatedwithcon-
comitant rituximab treatment (375mg/m2 for four weeks).
No adverse reactions were noted during the ﬁrst two weeks
of rituximab induction. However, the patient developed
mild, bilateral ocular pruritis and lacrimation three to four
weeks within the induction cycle. Maintenance treatment
with rituximab (four weekly doses of 375mg/m2 every
six months) was pursued since the patient tolerated the2 Advances in Hematology
Figure 1: Bone marrow trephine core biopsy shows a single
paratrabecular lymphoid aggregate, characteristic of bone marrow
involvement by follicular lymphoma (hematoxylin and eosin stain,
20x).
Figure 2: Left conjunctival biopsy with diﬀuse lymphocytic
inﬁltrate (hematoxylin and eosin stain, 20x).
induction cycle without severe complications. Nevertheless,
the bilateral eye inﬂammation became more pronounced
after the second cycle of maintenance therapy. In addition
to the pruritis and lacrimation, she also developed intense,
bilateral periocular erythema, moderate edema, and pain
as well as gradual blurring of vision. These manifestations
were more prominent in the left eye. She had neither new
lymphadenopathy nor any other systemic symptoms. She
was then referred to an ophthalmologist for abatement of
symptoms and was given topical steroid drops.
Concurrent CT of the chest, abdomen, pelvis, and
bilateralorbits revealedno evidence ofmalignancy ordisease
recurrence. A left eye conjunctival biopsy was performed
to further exclude the possibility of an underlying neo-
plasm. The biopsy showed an intact epithelium, prominent
lymphatic channels with increased stromal lymphocytes
(Figure 2). The majority of the lymphocytes expressed CD3,
aT - c e l lm a r k e r( Figure 3) ,w i t ho n l yr a r ec e l l sr e a c t i v ef o r
CD79a, a B-cell marker (Figure 4). The CD20 stain was
negative (Figure 5).
The severe ocular symptoms gradually subsided within
approximately four to six weeks after the last dose of the
second rituximab maintenance cycle. However, mild inﬂam-
mation of the left eye persisted. Moreover, exacerbation of
the left eye conjunctivitis was noted one week after the
patient received her initial rituximab dose on the third cycle
Figure 3: The vast majority of the lymphoid cells in the left
conjunctival biopsy are CD3-positive T lymphocytes (immunoper-
oxidase staining, 40x).
Figure 4: Rare B lymphocytes are positive for CD79a (left
conjunctiva, immunoperoxidase staining, 40x).
of maintenance regimen. Rituximab was discontinued, and a
followup ophthalmology visit was made. Topical antibiotic
and steroid drops were utilized for approximately seven
days. Two to three weeks after the termination of rituximab,
the patient’s conjunctivitis has markedly subsided and has
completely resolved in the succeeding eight weeks.
3. Discussion
The eﬃcacy of rituximab as a combination therapy or a
single, maintenance regimen has been well documented
in the treatment of non-Hodgkin’s lymphoma, including
the follicular subtype [1–5]. Recent evidence that the use
of maintenance rituximab signiﬁcantly prolongs disease-
free survival in patients with follicular histology, and with
minimal toxicity, further suggests that more patients may
be treated with this agent in the future [7]. Indeed, this
monoclonal antibody has been referred to as “the most
important advance in the treatment of B-cell lymphoma in
the past 30 years” [8].
Toxicity related to this therapy includes fever, chills,
urticaria, bronchospasm, hypotension, elevated heart rate,
and infrequently, rhinitis, and lacrimation [4, 5]. Only
one case of transient conjunctivitis associated with ritux-
imab infusion has been reported in literature, thus far
[6]. However, in contrast to the aforementioned case, ourAdvances in Hematology 3
Figure 5: The lymphocytes are negative for CD20 (left conjunctiva,
immunoperoxidase staining, 40x).
patient developed a delayed-type, hypersensitivity reaction,
manifesting as persistent, chronic conjunctivitis.
Conjunctival inﬂammation can be triggered by irrita-
tive substances, allergens, or underlying viral or bacterial
infections. In particular, immunocompromised or immuno-
suppressed states as a consequence of immune incapaci-
tating disease processes or the use of medications, such
as immunosuppressants or chemotherapy, increase the risk
of acquiring infections [9], and hence, conjunctivitis. In
addition, chemotherapy agents themselves, such as cytosine
arabinoside,maybeirritatingtotheconjunctivabasedonthe
drug concentration present in tears [10].
Inordertoexcludeaneoplasticprocesssuchasmetastatic
involvement of the conjunctiva, a biopsy with immunohis-
tochemical analysis was accomplished. We have pursued an
auxiliary B-cell marker investigation such as immunohisto-
chemicalstainingforCD79a,inadditiontoCD20toevaluate
the presence of malignant B lymphocytes that may have lost
surface expression of CD20 after treatment with rituximab
[11]. Predominance of CD3 reactive T lymphocytes with
onlyrare,scatteredBlymphocytespositiveforCD79afurther
substantiated a reactive process.
The exact pathophysiologic mechanism as to how rit-
uximab triggers conjunctivitis is not yet clearly elucidated,
but it can possibly be attributed to complement activation
with release of cytokines [12]. Myelosuppression and decline
in selected immunoglobulin levels and humoral function,
as a result of rituximab’s anti-CD20 eﬀect [4, 12, 13], may
also impair immune response. As such, conjunctival inﬂam-
mation could be prompted or aggravated by concomitant,
opportunistic infections.
4. Conclusion
Our case emphasizes a rare but clinically signiﬁcant occur-
rence of rituximab-associated chronic conjunctivitis. Aware-
ness of this particular adverse reaction is needed by the
prudentclinician,primarilyastheroleofrituximabexpands.
Consent. Written informed consent was obtained from the
patient for publication of this case report and accompanying
images. A copy of the written consent is available for review
by the Editor-in-Chief of this journal.
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